Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. Its Integrated Drug Creation platform combines artificial intelligence (AI) models with a synthetic biology data engine, enabling the design of therapeutics that address challenging therapeutic targets. Its approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Alongside collaborations with pharmaceutical, biotech, tech, and academic companies, the Company is advancing its own pipeline of AI- designed therapeutics. These include ABS-101, an antibody to treat inflammatory bowel disease (IBD), as well as other indications, and ABS-201, for hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern baldness. The company has four wholly owned, internally developed programs focusing on cytokine biology. Its other pipeline programs include ABS-301 and ABS-501.
Follow-Up Questions
Qui est le CEO de Absci Corp ?
Mr. Sean Mcclain est le Chief Executive Officer de Absci Corp, il a rejoint l'entreprise depuis 2011.
Quelle est la performance du prix de l'action ABSI ?
Le prix actuel de ABSI est de $3.94, il a decreased de 0.25% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Absci Corp ?
Absci Corp appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Absci Corp ?
La capitalisation boursière actuelle de Absci Corp est de $589.1M
Est-ce que Absci Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour Absci Corp, y compris 3 achat fort, 10 achat, 1 maintien, 0 vente et 3 vente forte
